United Therapeutics to Pay $250 Million for First US Approval of Inhaled Ralinepag
United Therapeutics will pay $250 million for the first US approval of inhaled ralinepag for pulmonary arterial hypertension.
Related stories
Comscore Reports Q3 Revenue Down 14.3%, Targets $20M–$25M Cost Savings
Comscore reported third-quarter 2026 revenue of $76.2 million, down 14.3% year over year. Net loss was $65.5 million, including a $57.3 million non-cash goodwill impairment and $5.
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
Sherritt to Temporarily Lay Off About 280 Canadian Employees
Sherritt says the layoffs will affect 47% of its Canadian workforce and last about 90 days as it works to preserve liquidity and restore refining operations in Fort Saskatchewan, A
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
JELD-WEN Reports Third-Quarter 2026 Revenue of $798.5 Million
Net revenues fell 1.4% year over year to $798.5 million. The company posted a $17.2 million net loss, compared with a $367.6 million loss a year earlier, and maintained its 2026 re
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
Latham Group Reports Q3 Results, Announces $100 Million Buyback
Latham Group reported third-quarter net sales of $182.2 million, up 12.5% year over year, net income of $12.1 million and Adjusted EBITDA of $45.3 million, up 18.1%. It approved a
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
Amwell Reports Q3 Revenue Above Guidance, Issues Q4 Outlook
Amwell reported third-quarter revenue of $49.0 million, exceeding its previously provided guidance range. Net loss was $11.0 million, versus $9.6 million in Q2, and adjusted EBITDA
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
EagleRock Land Reports Q3 Results and Updates 2026 EBITDA Guidance
EagleRock Land reported third-quarter revenue of $43.3 million, net income of $11.3 million, Adjusted EBITDA of $34.0 million and free cash flow of $31.8 million. It updated full-y
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC